Sorry, but I have to agree with TJ here. The NVS sales are a slight disappointment, and you were just saying last week that they would be a big positive.
Don't get me wrong, I don't think it's negative, but rather a non-event. I believe it is still too early for European sales data to carry any weight. most analysts predicted the slow start before sales pick up when all countries in EMA are able to use jakavi.
Does anybody have any idea what percentage of the EMA has already figured out their pricing/are able to prescribe jakavi as of today?